Literature DB >> 9112510

Prognostic factors for relapse in stage I testicular seminoma treated with surveillance.

P Warde1, M K Gospodarowicz, D Banerjee, T Panzarella, L Sugar, C N Catton, J F Sturgeon, M Moore, M A Jewett.   

Abstract

PURPOSE: We sought to identify prognostic factors predictive of disease progression in patients with clinical stage I seminoma on surveillance following orchiectomy.
MATERIALS AND METHODS: Between January 1981 and December 1993, 201 patients 20 to 86 years old (median age 34) with clinical stage I seminoma were placed on surveillance following orchiectomy. The potential prognostic factors studied included age, tumor size, mitotic count, S phase fraction, ploidy, presence of small vessel invasion, syncytiotrophoblasts and tumor infiltrating lymphocytes, expression of beta-human chorionic gonadotropin and low molecular weight keratin on immunohistochemistry.
RESULTS: With a median followup of 6.1 years (range 1.3 to 12.3) 31 patients had relapse for an actuarial 5-year relapse-free rate of 84.9%. The 5-year actuarial survival rate was 97.1% and the cause specific survival rate was 99.5%. On univariate analysis factors predictive of relapse were tumor size (5-year relapse-free rate 88 and 67% for tumors 6 cm. or less and greater than 6 cm., respectively, p = 0.004), age (5-year relapse-free rate 79 and 91% for age 34 years or younger versus older than 34 years, respectively, p = 0.009) and presence of small vessel invasion (5-year relapse-free rate 86 versus 69%, p = 0.01). On multivariate analysis age and tumor size were predictive of relapse, while small vessel invasion approached statistical significance. The risk of relapse in 57 patients with none of the 3 adverse prognostic factors (age greater than 34 years, tumor 6 cm. or smaller and no small vessel invasion) was 6%.
CONCLUSIONS: We identified age, size of the primary tumor and small vessel invasion as important prognostic factors for relapse in patients with stage I seminoma treated with surveillance. Further followup and assessment of biological factors are needed to optimize selection of patients at a high risk for relapse who should receive immediate postoperative therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9112510

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  [Testicular cancer--is there an indication for adjuvant or neoadjuvant systemic therapy?].

Authors:  S Langenkamp; P Albers
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

Review 3.  [Diagnosis, treatment and follow-up of testicular cancer].

Authors:  Susanne Krege
Journal:  Urologe A       Date:  2017-12       Impact factor: 0.639

Review 4.  [Therapeutical options for seminomas at clinical stage I-IIA/B].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

5.  Testicular neoplasms. Evaluation of the experience during 25 years in a military hospital.

Authors:  Ramón Diz-Rodríguez; Miguel Vírseda-Chamorro; Pedro Paños-Lozano; Antonio Colmenarejo Rubio; Ignacio Arance-Gil; Ana Moreno Posadas
Journal:  Clin Transl Oncol       Date:  2006-09       Impact factor: 3.405

6.  The Evolving Management of Patients With Clinical Stage I Seminoma.

Authors:  Richard S Matulewicz; Daniel T Oberlin; Joel Sheinfeld; Joshua J Meeks
Journal:  Urology       Date:  2016-08-12       Impact factor: 2.649

7.  Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.

Authors:  Salvatore Ulisse; Enke Baldini; Marcella Mottolese; Steno Sentinelli; Patrizia Gargiulo; Brancato Valentina; Salvatore Sorrenti; Anna Di Benedetto; Enrico De Antoni; Massimino D'Armiento
Journal:  BMC Cancer       Date:  2010-04-19       Impact factor: 4.430

8.  Acute cord compression secondary to spinal relapse of testicular seminomas.

Authors:  Yau Hong Ng; Henry Sun Sien Ho; Naresh Satyanarayan Kumar
Journal:  BMJ Case Rep       Date:  2013-04-17

9.  Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).

Authors:  Konstantinos Koutsoukos; Kimon Tzannis; Christos Christodoulou; Vasilios Karavasilis; Charalambos Bakoyiannis; Thomas Makatsoris; C N Papandreou; Dimitrios Pectasides; Meletios A Dimopoulos; Aristotelis Bamias
Journal:  World J Urol       Date:  2015-09-26       Impact factor: 4.226

10.  Prediction of metastatic status in non-seminomatous testicular cancer.

Authors:  C G Ruf; S Sachs; N Khalili-Harbi; H Isbarn; W Wagner; C Matthies; V Meineke; M Fisch; F K Chun; M Abend
Journal:  World J Urol       Date:  2013-10-29       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.